Aug 18, 2026 · 6 min
Klarna cuts outlook as Amylyx rallies on trial results
Klarna Plunges, Amylyx Pharma Soars, Bath & Body Works Rallies
The episode shows how weaker consumer activity, clinical evidence, analyst upgrades, and earnings surprises are pulling premarket stocks in opposite directions.
- 1Klarna lowered its revenue outlook as weaker consumer activity pressured the fintech company’s premarket shares.
- 2Amylyx Pharmaceuticals surged after reporting positive late-stage trial results, making clinical news the session’s clearest catalyst.
- 3Fabrinet fell despite beating quarterly expectations, while Bath & Body Works rallied after a Citi upgrade.
Don't miss
Amylyx Pharmaceuticals surges on positive late-stage trial results, sharply contrasting with Klarna’s outlook-driven decline.
The brief
Klarna’s shares fell after the company lowered its revenue outlook and reported weaker consumer activity, turning a familiar fintech growth story into a warning about demand.
Amylyx Pharmaceuticals moved sharply higher on positive late-stage trial results, while Fabrinet declined despite beating quarterly expectations—evidence that the market rewards catalysts selectively.
Bath & Body Works rallied after a Citi upgrade, adding an analyst-driven move to a morning shaped by contrasting company-specific news.
The episode then shifts from markets to cities, previewing a discussion of AI-enabled urban systems, infrastructure, and Dubai’s long-term response to rapid population growth.
Taken together, the lineup shows why premarket moves require interpretation: forecasts, trial results, analyst views, and operating performance can point in different directions.
What was said on this episode
8 statements · 6 positive · 1 negative · 1 neutral
Klarna’s second-quarter active consumers fell short of expectations.
“the number of active consumers, that's a big metric for them for the second quarter, missed expectations.”
Listen at 0:53
Amylyx’s experimental drug performed well in trials for post-bariatric-surgery hypoglycemia.
“they have a... an experimental drug that actually did very well in clinical trials for folks who experienced low blood sugar after bariatric surgery.”
Listen at 1:50
Amylyx plans to seek full FDA approval for its experimental drug.
“now they're going to take that to the FDA to try to get full approval.”
Listen at 2:00
Fabrinet’s fourth-quarter results exceeded Wall Street targets.
“fourth quarter results, topping Wall Street targets.”
Listen at 2:33
Bath & Body Works will release earnings next Wednesday.
“this Bath & Body Works is going to be out with earnings next Wednesday.”
Listen at 3:15
AI will accelerate and compress processes in smart-city systems.
“AI will allow in the smart city space to compress a lot of things. The speed will change.”
Listen at 4:09
Dubai responded effectively to its sudden population increase.
“they reacted very well to it.”
Listen at 4:35
Dubai has a long-term urban planning vision uncommon worldwide.
“They have a long-term urban planning vision, which again doesn't happen everywhere in the world.”
Listen at 4:37
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Klarna
Bloomberg Audio StudiosListen to the full episode and explore every guest, topic, and moment on PodLume.